Anila Lingamneni Sells 2,305 Shares of Haemonetics Co. (NYSE:HAE) Stock

Haemonetics Co. (NYSE:HAE) EVP Anila Lingamneni sold 2,305 shares of the stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $95.00, for a total value of $218,975.00. Following the transaction, the executive vice president now owns 12,295 shares in the company, valued at $1,168,025. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Haemonetics Stock Performance

NYSE HAE opened at $92.59 on Friday. The business’s 50-day simple moving average is $83.98 and its 200-day simple moving average is $82.88. The firm has a market capitalization of $4.70 billion, a P/E ratio of 37.64, a P/E/G ratio of 2.23 and a beta of 0.34. Haemonetics Co. has a 1-year low of $70.74 and a 1-year high of $97.13. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.92 and a quick ratio of 1.76.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.10. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The company had revenue of $336.20 million during the quarter, compared to the consensus estimate of $320.84 million. During the same period in the previous year, the firm earned $0.85 earnings per share. Haemonetics’s revenue for the quarter was up 10.1% on a year-over-year basis. Equities analysts predict that Haemonetics Co. will post 3.95 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on HAE. Barrington Research reiterated an “outperform” rating and set a $105.00 price objective on shares of Haemonetics in a report on Friday, April 12th. StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, TheStreet cut shares of Haemonetics from a “b-” rating to a “c+” rating in a research note on Thursday, February 29th.

Institutional Trading of Haemonetics

A number of institutional investors have recently added to or reduced their stakes in HAE. Raymond James & Associates boosted its position in shares of Haemonetics by 11.6% in the third quarter. Raymond James & Associates now owns 32,801 shares of the medical instruments supplier’s stock worth $2,938,000 after buying an additional 3,421 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Haemonetics by 58.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,446 shares of the medical instruments supplier’s stock valued at $1,204,000 after acquiring an additional 4,959 shares in the last quarter. TD Asset Management Inc purchased a new stake in shares of Haemonetics during the third quarter valued at approximately $2,114,000. Carmel Capital Partners LLC acquired a new position in shares of Haemonetics during the third quarter worth $30,000. Finally, Panagora Asset Management Inc. purchased a new position in shares of Haemonetics in the third quarter valued at $3,833,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.